Date: 2013-07-09
Type of information: Services contract
Compound: genomics technologies and computational biology capabilities to validate preclinical models
Company: Blackfield (Germany) AstraZeneca (UK)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details: * On July 9, 2013, Blackfield has announced that it has entered a collaboration with AstraZeneca. Under the terms of the agreement, Blackfield will apply its genomics technologies and computational biology capabilities to validate preclinical models in support of one of AstraZeneca’s oncology drug development programs. The collaboration with AstraZeneca marks Blackfield’s fourth partnership with a major pharmaceutical company within one year of starting up. Earlier this year Blackfield entered service agreements with Janssen Pharmaceuticals, Inc. (a division of Johnson & Johnson), Merck KGaA and Boehringer Ingelheim.
Financial terms:
Latest news:
